- Home
- PBFS vs CRVS Comparison
PBFS vs CRVS Comparison
Compare PBFS & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PBFS
- CRVS
- Stock Information
- Founded
- PBFS 1889
- CRVS 2014
- Country
- PBFS United States
- CRVS United States
- Employees
- PBFS N/A
- CRVS N/A
- Industry
- PBFS Banks
- CRVS Biotechnology: Pharmaceutical Preparations
- Sector
- PBFS Finance
- CRVS Health Care
- Exchange
- PBFS Nasdaq
- CRVS Nasdaq
- Market Cap
- PBFS 287.0M
- CRVS 305.4M
- IPO Year
- PBFS N/A
- CRVS 2016
- Fundamental
- Price
- PBFS $12.31
- CRVS $4.11
- Analyst Decision
- PBFS
- CRVS Strong Buy
- Analyst Count
- PBFS 0
- CRVS 4
- Target Price
- PBFS N/A
- CRVS $15.00
- AVG Volume (30 Days)
- PBFS 35.7K
- CRVS 1.2M
- Earning Date
- PBFS 05-09-2025
- CRVS 08-05-2025
- Dividend Yield
- PBFS N/A
- CRVS N/A
- EPS Growth
- PBFS 27.31
- CRVS N/A
- EPS
- PBFS 0.80
- CRVS N/A
- Revenue
- PBFS $88,641,000.00
- CRVS N/A
- Revenue This Year
- PBFS N/A
- CRVS N/A
- Revenue Next Year
- PBFS N/A
- CRVS N/A
- P/E Ratio
- PBFS $15.62
- CRVS N/A
- Revenue Growth
- PBFS 21.19
- CRVS N/A
- 52 Week Low
- PBFS $10.07
- CRVS $1.78
- 52 Week High
- PBFS $12.65
- CRVS $10.00
- Technical
- Relative Strength Index (RSI)
- PBFS 65.28
- CRVS 53.94
- Support Level
- PBFS $11.91
- CRVS $3.79
- Resistance Level
- PBFS $12.65
- CRVS $4.31
- Average True Range (ATR)
- PBFS 0.40
- CRVS 0.29
- MACD
- PBFS 0.06
- CRVS 0.00
- Stochastic Oscillator
- PBFS 92.80
- CRVS 72.64
About PBFS Pioneer Bancorp Inc.
Pioneer Bancorp Inc is involved in providing banking services. These services include Personal services such as Checking, Savings, eBanking Cards, and Business services such as Business Deposit and operating Accounts, Business eBanking, and Business loans. Some of the other services of the company include Government Banking, Wealth Management, Benefits Consulting and Insurance.
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).